Search Results - "Martinez Lago, N."

Impact of risk factors on the efficacy and complications of ultrasound-guided percutaneous liver biopsy of space-occupying lesions by Varela-Ponte, R, Martínez-Lago, N, Vieito-Villar, M, Carreira-Villamor, J Martin

“…Ultrasound-guided percutaneous liver biopsy is considered the technique of choice for the histological diagnosis of space-occupying lesions, given its high…”
Get full text

Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction by Martínez-Lago, N., Vieito-Villar, M., Vidal-Insua, Y., Padin-Iruegas, M. E., Vazquez-Rivera, F., Candamio-Folgar, S., Lopez-Lopez, R.

“…Purpose In high risk gastric and gastroesophageal adenocarcinoma, adjuvant radiochemotherapy with 5-fluorouracil bolus became a standard adjuvant treatment,…”
Get full text

FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial by Fernández Montes, A., Martinez Lago, N., De la Cámara Gómez, J., Covela Rúa, M., Cousillas Castiñeiras, A., Gonzalez Villarroel, P., Méndez Méndez, J.

Get full text

In the pathway to response: Is aflibercept an optimal treatment for RASwt mCRC patients after progression to 1st line containing anti-EGFR? by Mata Velasco, E, González-Flores, E, Juez Martel, I, Alonso, V, Iranzo Gomez, P, Martinez Lago, N, Lopez, C, Cabrera Romero, J M, Safont Aguilera, M J, Ruiz Casado, A, Salgado Fernandez, M, González Astorga, B, Escudero, P, Rivera Herrero, F, Pericay Pijaume, C, Vera, R

Get full text

Differences in outcome according to chemotherapy backbone and maintenance treatment in HER2 positive metastatic gastric cancer (GC) or gastroesophageal junction (GEJ) by Martinez Lago, N., Candamio Folgar, S., Grande Ventura, C., Salgado Fernandez, M., De la Camara Gomez, J., Méndez Méndez, J.C., Arias Ron, D., Vazquez, F., Reboredo Lopez, M., Vidal Ínsua, Y., Graña Suarez, B., Jorge Fernandez, M., Brozos Vazquez, M.E., Pellon Augusto, M.L., Prato Varela, J., Gonzalez Villarroel, P., Fernandez Montes, A.

Get full text

Efficacy and safety of trifluridine/tipiracil in third-line and beyond for the treatment of patients with metastatic colorectal cancer in routine clinical practice: patterns of use and prognostic nomogram by Fernandez Montes, A., Vazquez Rivera, F., Martinez Lago, N., Covela Rúa, M., Cousillas Castiñeiras, A., Gonzalez Villarroel, P., de la Cámara Gómez, J., Méndez Méndez, J. C., Salgado Fernández, M., Candamio Folgar, S., Reboredo López, M., Carmona Campos, M., Gallardo Martín, E., Jorge Fernández, M., Pellón Augusto, M. L., París Bouzas, L., García Gómez, J.

“…Introduction Trifluridine/tipiracil combination has shown a benefit over placebo in the treatment of patients with chemorefractory metastatic colorectal cancer…”
Get full text

P-165Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matter? by Fernandez Montes, A, Martinez Lago, N, Covela Rua, M, De la Camara Gomez, J, Mendez Mendez, JC, Gonzalez Villarroel, P

Get full text

Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry by Plazas, J. Gallego, Arias-Martinez, A., Lecumberri, A., Martínez de Castro, E., Custodio, A., Cano, J.M., Hernandez, R., Montes, A.F., Macias, I., Pieras-Lopez, A., Diez, M., Visa, L., Tocino, R.V., Lago, N. Martínez, Limón, M.L., Gil, M., Pimentel, P., Mangas, M., Granja, M., Carnicero, A.M., Pérez, C. Hernández, Gonzalez, L.G., Jimenez-Fonseca, P., Carmona-Bayonas, A.

“…Recommendations for research articles include the use of the term sex when reporting biological factors and gender for identities or psychosocial or cultural…”
Get full text

The prognostic value of systemic inflammatory factors in patients with HER2-positive metastatic gastric cancer by Martínez-Lago, N., Lesta-Mellid, R., Rendo, C. Reboredo, Reboredo-Lopez, M., Aparicio, L. Antón

Get full text

Impact of risk factors on the efficacy and complications of ultrasound-guided percutaneous liver biopsy of space-occupying lesions by Varela-Ponte, R., Martínez-Lago, N., Vieito-Villar, M., Martin Carreira-Villamor, J.

“…Ultrasound-guided percutaneous liver biopsy is considered the technique of choice for the histological diagnosis of space-occupying lesions, given its high…”
Get full text

Functional imaging in neuroendocrine tumors: assessment of molecular heterogeneity using [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT by Nogareda Seoane, Z., Mallón Araújo, M.C., Calatayud Cubes, A., Barberán Corral, C., Domínguez Novoa, Y., Cousillas Castiñeira, A., Martínez Lago, N., de Matías Leralta, J.M., Pubul Nuñez, V.

“…The aim of the study was evaluate the diagnostic performance of [68Ga]Ga-DOTA-TOC and [18F]FDG PET/CT in patients with histologically proven neuroendocrine…”
Get full text

Is there any affordable and reliable score in local gastric cancer? by Cousillas Castiñeiras, A., Gallardo Martin, E., Fernández Montes, A., Covela Rúa, M., Carmona Campos, M., Salgado Fernandez, M., Pellón Augusto, M., Vidal Insua, Y., Gonzalez Villarroel, P., Martínez-Lago, N., De la Cámara Gómez, J., Candamio Folgar, S., Brozos Vázquez, E., Fernandez, M. Jorge, Vázquez Rivera, F., Méndez Méndez, J., Quintero Aldana, G., Constenla, M.

Get full text

Efficacy and safety of FOLFIRI/Aflibercept (FA) in an elderly population with metastatic colorectal cancer (mCRC) after the failure of an oxaliplatin-based regimen by Martínez-Lago, N., Carmona Campos, M., Gonzalez Villarroel, P., Salgado Fernandez, M., De la Cámara Gómez, J., Romero Reinoso, C., Cousillas Castiñeiras, A., Méndez Méndez, J., Vidal Insua, Y., Reboredo Rendo, C., Covela Rúa, M., Quintero Aldana, G., Graña Suarez, B., Carral Maseda, A., Jorge Fernandez, M., Pellón Augusto, M., Grande Ventura, C., Gallardo Martin, E., Fernández Montes, A., Reboredo-Lopez, M.

Get full text

Role of systemic inflammatory factors in gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated with peptide receptor radionuclide therapy (PRRT): From biology to theragnosis by Abou-Jokh Casas, E., Martínez-Lago, N., Mallón Araujo, M.C., Cabezas Agrícola, J.M., Nogareda Seoane, Z., Cousillas Castiñeira, A., Ruibal Morell, A., Pubul Núñez, V.

“…Systemic inflammatory factors have been validated as indicators of ongoing systemic inflammation that could be predictive markers of poor prognosis for…”
Get full text

P-051Preliminary clinical and pathologic characteristics of patients treated in second-line (2L) with 25 cycles (Cy) or more of FOLFIRI + Aflibercept (FA) by Pericay, C, Martinez-Lago, N, Corral, M, Macias Declara, I, Donnay, O, Juez Martel, I, Garcia-Paredes, B, Mendez Mendez, JC, Cacho Lanvin, D, Gonzalez-Astorga, B, Ruiz Casado, A, Delgado Urena, MT, Rodriguez, N, Calderero Aragon, V, Mata Velasco, E, Barrera Ramirez, JA, Macarulla, T

Get full text

P-089FOLFIRI plus panitumumab as second-line treatment in mutated RAS metastatic colorectal cancer patients who converted to wild type RAS after receiving first-line FOLFOX/CAPOX plus bevacizumab-based treatment: Phase II CONVERTIX trial by Fernández Montes, A, Martinez Lago, N, De la Cámara Gómez, J, Covela Rúa, M, Cousillas Castiñeiras, A, Gonzalez Villarroel, P, Méndez Méndez, J

Get full text

4CPS-106 Multi-state model to estimate the optimal duration of first-line chemotherapy in advanced gastric cancer: data from the national registry agamenon by Arias, A, Alvarez Manceñido, FJ, Martínez Torrón, AM, Rodriguez Palomo, A, Alaguero Calero, MÁ, Aguado, G, Sánchez Cánovas, M, Martínez Lago, N, Hernández Pérez, C, Lozano-Blázquez, A

“…BackgroundTo date, there has been no phase III trial to establish the optimal duration of first-line chemotherapy for patients with advanced gastric cancer…”
Get full text

1394P Frequentist and Bayesian analysis of second line treatment effectiveness in AGAMENON-SEOM gastric cancer registry by Martinez Lago, N., Carmona-Bayonas, A., Pieras Lopez, A., Ramchandani, A., Longo, F., Martin Carnicero, A., Granja Ortega, M., Calvo, A., Hernandez, R., Castro Unanua, N., Assaf, J.D., Azkarate, A., Hernandez-Perez, C., Camara, J.C., Saurí, T., Custodio, A., Cano, J.M., Fernandez Montes, A., Martinez de Castro, E., Gallego, J.

Get full text

P-165 Efficacy and toxicity of FOLFIRI / aflibercept in second line colorectal cancer in real life population, retrospective study. Does first line matter? by Fernandez Montes, A., Martinez Lago, N., Covela Rúa, M., De la Cámara Gómez, J., Méndez Méndez, J.C., Gonzalez Villarroel, P.

Get full text

588PEfficacy and safety of FOLFIRI/Aflibercept (FA) in elderly population with mCRC after failure of oxaliplatin-based chemotherapy by Lago, N Martinez, Campos, M Carmona, Villarroel, P Gonzalez, Fernandez, M Salgado, la, J De, Gomez, Camara, Reinoso, C Romero, Castiñeiras, A Cousillas, Insua, Y Vidal, Mendez, J C Mendez, Rendo, C Reboredo, Rua, M Covela, Aldana, G Quintero, Suarez, B Graña, Maseda, A Carral, Fernandez, M Jorge, Augusto, M L Pellon, Ventura, C Grande, Martin, M E Gallardo, Montes, A Fernández, Lopez, M Reboredo

“…Abstract Background Aflibercept (Af) significantly improves progression-free (PFS) and overall survival (OS) when added to FOLFIRI, in the overall population…”
Get full text